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Supplementary Figure 1.  A) Homology modelled structure of human OPRK1 (PDB id 2a0d), B) Highlighted human residues in the OPRK1 C-
terminal region, C) Highlighted rodent residue substitutions in the OPRK1 C-terminal region 
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Supplementary Figure 2.  Pilot study to examine the abilities of single concentrations of different κ receptor agonists to inhibit cholinergically-
mediated contractions of human descending colon evoked by electrical field stimulation.  All EC50s are for the human receptor and except where 
stated are taken from White, K.L. et al. (Identification of novel functionally selective κ-opioid receptor scaffolds. Mol. Pharmacol. 85, 83-90, 
2014); the remainder (*) are data from the experiments documented in the body of the accompanying paper, measuring ability to recruit G 
Proteins (BRET) and internalise (TR-FRET) the receptor.  Similarly, the data for ICI204448 and asimadoline, obtained using human colon in the 
presence of L-NAME 300 µM, are from the experiments found in the body of the accompanying paper. For the new experiments with human 
colon, dynorphin A 1-13, (-) U50488 and U62066 (each from Sigma, UK) were studied using tissue from two patients, again in the presence of 
L-NAME 300 µM: (1) Rectum, female, 33, cancer; (2) descending colon, male, 51, cancer. All strips displayed contractions during EFS 
(inhibited by κ agonism) and after-contractions (unaffected by each ligand).  
Ligand Recombinant human receptor Human intestine 
G protein pEC50 Arrestin pEC50 Concentration N % inhibition of contractions 
evoked during EFS 
Time to max effect 
(minutes) 
Dynorphin 1-13 8.68 ± 0.07 7.01 ± 0.07 1 µM 2 -30, -35 17, 11 
(-) U50488 9.06 ± 0.07 9.09 ± 0.09 1 µM  2 -44, -74 31, 27 
U62066 9.00 ± 0.05 
 
8.21 ± 0.10 1 µM  2 -39, -50 24, 24 
ICI204448 8.38 ± 0.09 
9.6 ± 0.1* 
8.48 ± 0.06 
7.7 ± 0.1* 
1 µM 6 -57 ± 10 13 ± 3  
Asimadoline 9.2 ± 0.1* 7.4 ± 0.1* 1 µM 6 -29 ± 4 40 ± 4 
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Supplementary Figure 3.  Detection of SNAP-kappa-opioid receptor at the surface of HEK293 cells.  As BG-Tb is not cell permeant, only 
receptors expressed at the cell surface and displaying the SNAP-tag outside the cell were labelled.  Data are means ± SD of a triplicate. 
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Supplementary Figure 4.  BRET was measured in HEK293 cells co-expressing Gαi1-Rluc8, β2 and Venus-γ2 (no receptor).  Cells were 
stimulated with increasing concentrations of ICI204448 and asimadoline.  Data are means ± SD of a representative experiment. 
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Supplementary Figure 5.  (a) Dose response of DALDA on MOR (Gi-coupled receptor) and (b) AVP on V2 (Gs-coupled receptor).  DALDA 
EC50 = 4.10-11M.  Data are means ± SD of a representative experiment. 
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Supplementary Figure 6.  a) Time course of V2 internalization with 1μM AVP. b) Dose response of AVP on V2 at T = 40 min. AVP EC50 = 
1.10-9M. Data are means ± SD of a representative experiment. 
 
 
 
 
 
 
 
 
 
 
 
